eClinical Provider DATATRAK joins SAS® Alliance to Offer Cloud-Based SAS® Drug Development
DATATRAK - Delivering clinical trial solutions from Concept to Cure(TM). (PRNewsFoto/DATATRAK International, Inc.)
CLEVELAND, June 19, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced their partnership with SAS to provide SAS® Drug Development as an extension of the DATATRAK ONE™ solution.
"As the innovator in cloud-based eClinical solutions, DATATRAK brings the power of SAS Drug Development to customers with our rapid integration capabilities," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "DATATRAK customers already enjoy real-time access to all of their study data with our unified platform. Adding SAS Drug Development to our arsenal gives users the power of SAS Analytics across all their unified data, accelerating the drug development process through greater data visibility and real-time analysis."
Aimed at transforming clinical research processes through repeatable, sustainable improvements, DATATRAK will work with SAS to make SAS Drug Development available in the cloud, providing data flow from DATATRAK ONE™ into SAS Drug Development. The seamless integration is designed to streamline work processes for a company-wide implementation across the breadth of a drug development program. Intended to support Clinical Data Interchange Standards Consortium (CDISC) standards, the integrated cloud-based solution will be designed to leverage DATATRAK's unified platform with workflows, document management, and analysis to support the current needs and future business growth of life sciences organizations.
SAS Drug Development helps organizations make informed clinical and business decisions; streamline and optimize analysis and reporting processes; assess safety and efficacy more effectively; and improve collaboration with business partners and regulatory authorities. It eases analysis and reporting for single trials as well as aggregated clinical data assets across multiple trials or therapies.
Join DATATRAK Thought Leaders:
Tweet: DATATRAK provides SAS® Drug Development in the cloud http://bit.ly/19PdBRl
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 15, 2013 announcing its results for the first quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.